Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 10 peer-reviewed journal articles Updated
Hematology

The Genetic Engine of HCL: BRAF V600E

At a Glance

Almost all cases of Classic Hairy Cell Leukemia (HCL) are driven by the BRAF V600E genetic mutation. Identifying this mutation confirms a classic HCL diagnosis, distinguishes it from HCL-variant, and opens up targeted treatment options like BRAF inhibitors.

While the term “leukemia” refers to the type of cells involved, the true engine of Classic Hairy Cell Leukemia (HCL) is a specific genetic change called the BRAF V600E mutation [1][2]. Understanding this “biological engine” is the key to why HCL is treated differently than other blood cancers.

The BRAF V600E Mutation: The “On Switch”

In almost every single person with Classic HCL, a mutation occurs in the BRAF gene [2]. Normally, this gene acts like a carefully controlled switch that tells cells when to grow. In HCL, the V600E mutation gets stuck in the “on” position [1].

This stuck switch sends a constant signal to B-cells to survive and multiply when they shouldn’t. This genetic “typo” is so central to the disease that identifying it is now considered essential for a definitive diagnosis [1].

Why the Distinction Matters

HCL can look very similar to other rare blood cancers, but they have different biological “engines.” Your doctors use molecular testing to tell them apart because the treatments that work for one may not work for the others [3].

Feature Classic HCL HCL-Variant (HCL-v) Splenic Marginal Zone Lymphoma (SMZL)
Primary Driver BRAF V600E [1] Often MAP2K1 [4] Various other markers [5]
CD25 Marker Usually Positive [5] Usually Negative [5] Usually Negative [5]
Typical Course Indolent (Slow) [6] More Aggressive Indolent (Slow) [5]
Standard Treatment Purine Analogs [7] Often resistant to standard HCL drugs [3] Varies (often Rituximab) [5]

The Value of Precise Testing

Because HCL is so rare, specialized testing is vital. Doctors use highly sensitive tools like PCR (Polymerase Chain Reaction) to find the BRAF mutation even if only a few leukemia cells are present.

Confirming the BRAF V600E mutation does two important things for your care:

  1. Ensures the Right Diagnosis: It rules out HCL-variant (HCL-v), which often lacks the BRAF mutation and may involve a different mutation called MAP2K1 [4][8].
  2. Opens Targeted Options: If standard chemotherapy doesn’t work or the disease returns, knowing you have the BRAF mutation allows you to use targeted therapies (such as BRAF inhibitors, sometimes combined with MEK inhibitors) that specifically turn off that “stuck” switch [9].

In short, while the mutation is the “bad actor” that causes the disease, identifying it is the most powerful tool your medical team has for managing it effectively [10].

Common questions in this guide

What is the BRAF V600E mutation in Hairy Cell Leukemia?
The BRAF V600E mutation is a specific genetic change found in almost all cases of Classic Hairy Cell Leukemia. It acts like a stuck 'on' switch, constantly signaling B-cells to survive and multiply when they shouldn't.
How do doctors test for the BRAF mutation?
Doctors use highly sensitive molecular tests, such as Polymerase Chain Reaction (PCR), on your blood or bone marrow. This test can find the BRAF mutation even if only a very small number of leukemia cells are present.
Why is it important to distinguish Classic HCL from HCL-variant?
Classic HCL and HCL-variant are driven by different genetic mutations and respond differently to treatments. HCL-variant typically lacks the BRAF mutation, grows more aggressively, and is often resistant to standard classic HCL drugs.
What does it mean if my pathology report shows CD25?
The presence of the CD25 marker on your cells is a standard feature of Classic Hairy Cell Leukemia. Checking for CD25 helps your care team confirm you have the classic form rather than HCL-variant or another similar blood cancer.
How does having the BRAF mutation affect my HCL treatment options?
Knowing you have the BRAF mutation opens up targeted treatment options if standard therapies do not work. Your doctor can use specific drugs called BRAF inhibitors that directly target and turn off the mutated switch causing the cancer to grow.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Has my diagnosis been confirmed by molecular testing for the BRAF V600E mutation?
  2. 2.Does my pathology report show the presence of CD25 and Annexin A1, and how do these help confirm I have the classic form?
  3. 3.Was I tested for the MAP2K1 mutation, which is often found in the variant form of this disease?
  4. 4.How does knowing my specific genetic mutation change the treatment plan we are considering?
  5. 5.Are there specific targeted therapies, like BRAF inhibitors, that we should keep in mind for the future?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (10)
  1. 1

    Genomics of Hairy Cell Leukemia.

    Tiacci E, Pettirossi V, Schiavoni G, Falini B

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(9)):1002-1010 doi:10.1200/JCO.2016.71.1556.

    PMID: 28297625
  2. 2

    Hairy Cell Leukemia Masquerading as CD5+ Lymphoproliferative Disease: The Importance of BRAF V600E Testing in Diagnosis and Treatment.

    Soong D, Kumar P, Jatwani K, et al.

    JCO precision oncology 2021; (5()) doi:10.1200/PO.20.00518.

    PMID: 34250418
  3. 3

    Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group.

    Paillassa J, Maitre E, Belarbi Boudjerra N, et al.

    Cancers 2024; (16(12)) doi:10.3390/cancers16122185.

    PMID: 38927891
  4. 4

    Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions.

    Troussard X

    Expert review of hematology 2024; (17(12)):907-915 doi:10.1080/17474086.2024.2427660.

    PMID: 39535173
  5. 5

    Untangling hairy cell leukaemia (HCL) variant and other HCL-like disorders: Diagnosis and treatment.

    Troussard X, Maitre E

    Journal of cellular and molecular medicine 2024; (28(3)):e18060 doi:10.1111/jcmm.18060.

    PMID: 38095234
  6. 6

    Patients with relapsed/refractory hairy-cell leukemia.

    Paillassa J, Troussard X

    Cancer reports (Hoboken, N.J.) 2022; (5(3)):e1495 doi:10.1002/cnr2.1495.

    PMID: 34250762
  7. 7

    Classic hairy cell leukemia with an aggressive presentation.

    Fugere T, Harley S, Godbole A

    Proceedings (Baylor University. Medical Center) 2021; (34(6)):721-723 doi:10.1080/08998280.2021.1934344.

    PMID: 34733001
  8. 8

    Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience.

    Angelova EA, Medeiros LJ, Wang W, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018; (31(11)):1717-1732 doi:10.1038/s41379-018-0093-8.

    PMID: 29955146
  9. 9

    BRAF inhibitor: targeted therapy in hairy cell leukemia.

    Grever MR

    Blood 2016; (127(23)):2784-5 doi:10.1182/blood-2016-03-704262.

    PMID: 27282942
  10. 10

    Untangling the Strands of Hairy Cell Leukemia: The Clinicopathological Spectrum over Eleven Years at a Tertiary Care Center.

    Rai V, Manimaran P, Saha A, et al.

    Discoveries (Craiova, Romania) 2023; (11(2)):e166 doi:10.15190/d.2023.5.

    PMID: 37538441

This page is for informational purposes only and does not replace professional medical advice. Always consult your hematologist or oncologist about your specific diagnosis and genetic test results.

Get notified when new evidence is published on Classic hairy cell leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.